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This bulletin provides a comprehensive overview of many different aspects of sedative or tranquilliser, and anti-
depressant use in Ireland and Northern Ireland. It presents data gathered in the All Ireland Drug Prevalence Survey 
2006/2007 relating to sedatives or tranquillisers, and anti-depressants on a lifetime (ever used), last year (recent 
use) and last month (current use) basis. The bulletin also examines, age of first use, frequency of use, method of 
taking them, how they were obtained and the profile of typical sedative or tranquilliser, and anti-depressant users. 
The survey was carried out by Ipsos MORI in Ireland and by the Central Survey Unit of the Northern Ireland Statistics 
and Research Agency in Northern Ireland according to standards set by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA).
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Ireland  
– Key Findings
n	Prevalence rates were higher among older 
respondents – the lifetime prevalence rate 
for older adults aged 35-64 (15%) was 
more than twice that of young adults 
aged 15-34 (6%) for sedatives or 
tranquillisers and was also higher for those 
using anti-depressants (11% for older 
adults and 7% for younger adults).
n	Females reported higher prevalence rates 
than males for use of sedatives or 
tranquillisers, and anti-depressants across 
all time periods.
n	The average age respondents reported 
they had first used sedatives or 
tranquillisers was 29 years for males  
and 31 for females. The average age 
respondents reported they had first used 
anti-depressants was 34 years for males 
and 30 years for females.
n	A little more than half (57%) of current 
users of sedatives or tranquillisers, and 
nine-in-ten (91%) current users of anti-
depressants, took them daily or almost 
daily.
n	Most current users got their sedatives or 
tranquillisers (89%), and all (100%) got 
their anti-depressants, on prescription. 
However 11% reported that they had 
either got them from someone they 
knew or bought them without a 
prescription in a chemist.
n	Respondents who were separated or 
divorced reported higher prevalence  
rates for use of sedatives or tranquillisers, 
and anti-depressants across the three 
time periods.
n	Associations were found between various 
indicators of deprivation and higher 
prevalence rates. These indicators 
included: being dependent on the state 
long term, not being in paid work, lower 
levels of educational attainment and 
leaving education before 15 years of age.
Northern Ireland – 
Key Findings
n	Prevalence rates were higher among 
older respondents – the lifetime 
prevalence rate for older adults aged 35-
64 (26%) was more than twice than that 
of young adults aged 15-34 (12%) for 
sedatives or tranquillisers and was also 
higher for those using anti-depressants 
(27% for older adults and 14% for 
young adults).
n	Females reported higher prevalence rates 
than males for lifetime and last month use 
of sedatives or tranquillisers, and across 
all time periods for anti-depressants.
n	The average age respondents reported they 
had first used sedatives or tranquillisers was 
30 years for both males and females. The 
average age respondents reported they 
had first used anti-depressants was 34 
years for males and 31 years for females.
n	Approximately two-in-three (66%) 
current users of sedatives or tranquillisers, 
and nearly nine-in-ten (87%) current 
users of anti-depressants, took them  
daily or almost daily.
n	The vast majority of current users got their 
sedatives or tranquillisers (95%), and 
anti-depressants (96%), on prescription.
n	Respondents who were separated, 
divorced or widowed reported higher 
lifetime prevalence rates for sedatives  
or tranquillisers, and anti-depressants.
n	Associations were found between various 
indicators of deprivation and prevalence 
rates for sedatives or tranquillisers, and 
anti-depressants across all three time 
periods. Prevalence rates were higher 
among those in the lower socio-economic 
classifications, those not in paid work and 
those with low educational attainment or 
no qualifications.
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n	In all instances, use of sedatives or tranquillisers, and anti-
depressants was higher in Northern Ireland than in Ireland.
n	Older adults reported higher lifetime, last year and last month 
prevalence rates than younger adults for sedatives or 
tranquillisers, and anti-depressants in both Ireland and 
Northern Ireland.
n	Females reported higher prevalence rates than males for anti-
depressants in both jurisdictions across all time periods.
n	In Ireland and Northern Ireland the pattern of obtaining 
sedatives or tranquillisers, and anti-depressants was the same 
– nearly all users took tablets or syrup that they had obtained 
on prescription.
n	In both jurisdictions, lifetime prevalence rates for use  
of sedatives or tranquillisers, and anti-depressants were 
higher among respondents who were separated, divorced  
or widowed.
n	Associations were found between various indicators of 
deprivation and higher prevalence rates for sedatives or 
tranquillisers, and anti-depressants (lower socio-economic 
groups, not being in paid work and lower educational 
attainment). The pattern was similar in both Ireland and 
Northern Ireland.
Ireland and Northern Ireland Comparison – Key Findings
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Introduction
The survey was commissioned by the National Advisory 
Committee on Drugs (NACD) in Ireland and the Public Health 
Information and Research Branch (PHIRB), formerly known as 
the Drug and Alcohol Information and Research Unit (DAIRU), 
within the Department of Health, Social Services and Public 
Safety (DHSSPS) in Northern Ireland.
The main focus of the survey was to obtain prevalence rates for 
key illegal drugs, such as cannabis, ecstasy, cocaine and heroin, 
on a lifetime (ever used), last year (recent use), and last month 
(current use) basis. Similar prevalence questions were also asked 
of alcohol, tobacco, and other drugs such as sedatives or 
tranquillisers, and anti-depressants; attitudinal and demographic 
information was also sought from respondents.
Methodology
The questionnaire and methodology for this survey were based 
on best practice guidelines drawn up by the EMCDDA. The 
questionnaires were administered through face-to-face interviews 
with respondents aged between 15 and 64 normally resident in 
households in Ireland and Northern Ireland. Thus persons outside 
these age ranges, or who do not normally reside in private 
households, have not been included in the survey. This approach is 
commonly used throughout the EU and because of the exclusion of 
those living in institutions (for example, prisons, hostels) this type of 
prevalence survey is usually known as a general population survey.
Fieldwork for the survey was carried out between October 2006 
and May 2007 and the final achieved sample was 6,969 (4,967 
in Ireland and 2,002 in Northern Ireland). The response rate for 
the survey was 65% in Ireland and 62% in Northern Ireland. Area 
based sampling was applied in Ireland. The first stage involved 
stratifying by Health Board1/Regional Drugs Task Force (RDTF) area 
in Ireland. Within the Health Board/RDTF strata Electoral Divisions 
(EDs) were selected as areas. In Northern Ireland, the first stage 
involved stratifying by Health and Social Services Board (HSSB) 
areas and within the strata simple random sampling was used. 
The achieved sample was weighted by gender, age, RDTF area in 
Ireland and HSSB area in Northern Ireland, to maximise 
representativeness of the general population. The effects of 
stratification, clustering and weighting have been incorporated in 
the interval estimates (i.e. design effect adjusted). Details of the 
methodology have been published on the websites of the NACD 
(www.nacd.ie/) and the DHSSPS (www.dhsspsni.gov.uk/) in 
1 Since January 2005 the Health Boards in Ireland have undergone 
restructuring and are merged under one authority – the Health Service 
Executive. However for the purpose of comparison with 2002/3 data, we 
have continued to weight the data by the former Health Board areas as 
these correspond with the Regional Drugs Task Force (RDTF) structures. 
The above reference relates to the Health Board structures details in 
Bulletin 2: Drug Use in Ireland and Northern Ireland 2002/2003 Drug 
Prevalence Survey – Health Board (Ireland) & Health and Social Services 
Board (Northern Ireland) Results (Revised) June, 2005. 
comprehensive technical reports containing copies of the 
questionnaires used in each jurisdiction.
The Research Advisory Group (RAG) decided to change from 
using a pen and paper interviewing technique to computer-
assisted personal interviewing (CAPI), where the interviewer 
records responses electronically. This technique has several 
advantages: interviews can be administered more quickly; human 
error is minimised, yielding higher-quality data; and data input is 
managed more efficiently, thus cutting costs.2
What is Prevalence?
The term prevalence refers to the proportion of a population 
who has used a drug over a particular time period. In 
general population surveys, prevalence is measured by 
asking respondents in a representative sample drawn from 
the population to recall their use of drugs. The three most 
widely used recall periods are: lifetime (ever used a drug), 
last year (used a drug in the last twelve months), and last 
month (used a drug in the last 30 days). Provided a sample 
is representative of the total population, prevalence 
information obtained from a sample can be used to infer 
prevalence in the population.
Lifetime prevalence refers to the proportion of the sample 
that reported ever having used the named drug at the time 
they were surveyed. A person who records lifetime 
prevalence may – or may not – be currently using the drug. 
Lifetime prevalence should not be interpreted as meaning 
that people have necessarily used a drug over a long period 
of time or that they will use the drug in the future.
Last year prevalence refers to the proportion of the sample 
that reported using a named drug in the year prior to the 
survey. For this reason, last year prevalence is often referred 
to as recent use.
Last month prevalence refers to the proportion of the 
sample that reported using a named drug in the 30 day 
period prior to the survey. Last month prevalence is often 
referred to as current use. A proportion of those reporting 
current use may be occasional (or first-time) users who 
happen to have used in the period leading up to the survey 
– it should therefore be appreciated that current use is not 
synonymous with regular use.
As with other European surveys, people over the age of 64 are 
excluded from this survey, as they grew up in an era when both 
the use and availability of illegal drugs were very limited. 
Therefore surveys with older people have, to date, shown very 
low rates of use even on a lifetime basis. This situation will 
change over time as the younger population grows older. Hence 
lifetime prevalence rates are likely to increase for a considerable 
period of time. When examining the data and comparing results 
over time, last year use is the best reflection of changes as it 
refers to recent use. Last month use is equally valuable as it 
refers to current use.
2 EMCDDA Handbook on Population Surveys.
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Understanding the Results  
in this Bulletin
First results from the second Drug Prevalence Survey 
2006/2007 were published in Bulletin 1 (January 2008). They 
gave lifetime, last year and last month prevalence rates for key 
drugs for the Island of Ireland, Ireland and Northern Ireland.
Bulletin 2, published in June 2008, contained comparable 
information for Ireland and its constituent Regional Drugs Task 
Force areas (former Health Board areas) and Northern Ireland 
and its constituent Health and Social Services Board areas.
Bulletin 3 (2006/7 Drug Prevalence Survey: Cannabis Results) 
was published in December 2008, it examines age of first use; 
regular use; type of cannabis used; method by which cannabis is 
used; how and where cannabis is obtained; reasons for stopping 
use; attitudes to cannabis use and perceptions of risk, together 
with the typical profile of cannabis users.
Bulletin 4 (2006/7 Drug Prevalence Survey: Cocaine Results) 
was published in October 2008 and contains prevalence rates 
for the use of cocaine (cocaine powder or crack cocaine) and 
other information relating to cocaine use in Ireland and Northern 
Ireland for 2006/7 and also provides comparison information 
between 2002/3 and 2006/7. Results are given for all 
respondents, and are also presented by gender and by age 
(young adults aged 15-34 and older adults aged 35-64).
This bulletin (Bulletin 6) contains prevalence rates for the use  
of sedatives or tranquillisers, and anti-depressants and other 
information in relation to sedative or tranquilliser, and anti-
depressant use in Ireland and Northern Ireland for 2006/7. 
Results are given for all respondents, and are also presented by 
gender and by age (young adults aged 15-34 and older adults 
aged 35-64).
Readers should note that the total sample size for each group is 
given at the head of each column. All prevalence rates presented 
in the accompanying tables are rounded to one decimal place 
and are rounded to whole numbers in the text (except for 
percentages less than 1%).
As in all sample surveys, the greater the sample size the more 
statistically reliable are the results. Some of the differences in 
prevalence rates in the tables will be attributable to natural 
sample variations. Detailed confidence intervals for all prevalence 
rates contained in this bulletin can be found on the websites of 
the NACD and DHSSPS.
Invalid responses have been excluded from all analyses. 
Percentages may not always sum to 100 due to either the effect of 
rounding or where respondents could give more than one answer.
Where the figure 0.0% appears it does not mean that no-one has 
used the drug, rather it means that in this category no respondent 
reported use. The confidence intervals will provide a prevalence 
rate for all categories of drug use reported for lifetime, last year 
and last month, by gender and by age. Details regarding the 
calculation of confidence intervals can be found in the Technical 
Report published on the NACD and DHSSPS websites.
The Chi-Square test examined the association between 
categorical variables and the use of sedatives or tranquillisers,  
and anti-depressants in 2006/7. For the purpose of this study,  
a p-value of less than 0.05 indicated that a true association or 
relationship existed and the differences observed were not due 
to chance. The Z-test was used to compare differences between 
the Ireland and Northern Ireland results.
The measurement of the combined group of sedatives, tranquillisers 
and anti-depressants was changed between 2002/3 and 2006/7. 
In 2002/3 this drugs category was measured using one question 
while in 2006/7 two questions were asked and a more expansive 
list of drug categories was used (see technical report for further 
details). Given this change in measurement comparative analysis 
between 2002/3 and 2006/7 is not appropriate.
In an attempt to compare prevalence rates for sedatives or 
tranquillisers, and anti-depressants across different social classes/
socio-economic groups, the Standard Occupational Classification 
(SOC2000) was used in Ireland. The SOC2000 is based on the 
employment status, level of responsibility and qualifications, of 
the chief income earner within a household. Respondents were 
then coded into the following social grades:
SOC2000 Classification
A  Professionals, senior management and top civil servants
B  Middle management, senior civil servants, managers and 
owners of business
C1 Junior management and owners of small businesses
C2 Skilled manual workers and manual workers responsible  
for other workers
D Semi-skilled and unskilled manual workers, trainees and 
apprentices
E  All those dependent on the State long-term
Respondents were coded into the following social grades in 
Northern Ireland based on the National Statistics Socio-Economic 
Classification (NSSEC) as this has replaced Social Class based on 
Occupation and Socio-Economic Group (SEG). The NSSEC 
classification data shown in Table 21 relate to the individual. 
NSSEC Classification
n	Managerial and professional occupations
n	Intermediate occupations
n	Small employers and own account workers
n	Lower supervisory and technical occupations
n	Semi-routine and routine occupations
n	Never worked and long term unemployed
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Some of the tables for Ireland (Tables 8 – 10, 12 & 13) and 
Northern Ireland (Tables 21 – 23, 24 & 25) differ slightly with 
regard to response categories. Table 11: Ireland Age Education 
Ceased has no comparable table in Northern Ireland.
Future Publications
Further publications from the Drug Prevalence Survey will present 
analysis of data on polydrug use; alcohol data will also be 
published (for Ireland only).
Glossary
Sedatives and tranquillisers 
Sedatives and tranquillisers are commonly used terms for 
the same group of medicines which depress, slow down or 
calm the brain and central nervous system. They are mainly 
Benzodiazepines (“Benzos”) but other drugs with the same 
effects, e.g. Zolpidem and Zopiclone are included in this 
group. Medically they are often referred to as Hypnotics, 
which induce sleep and Anxiolytics or anti-anxiety agents. 
The same drug can be used as a hypnotic or as an anti-anxiety 
agent depending on the dose used and on the time of day 
that they are used. Hypnotics are used to treat insomnia 
(lack of adequate restful sleep) which is causing distress. 
Anxiolytics are also referred to as “minor tranquillisers”. 
Benzodiazepine anxiolytics are the most common type  
used to obtain relief of severe and disabling anxiety. 
Anti-depressants 
These are medicines used to treat conditions such as  
the low or sad mood, loss of interest or pleasure in  
daily activities, fatigue and energy loss usually known  
as Depression. Different drug classes are available on 
prescription to treat Depression. 
All of these drugs above are prescribed under medical 
supervision and can only be obtained by prescription  
from a pharmacist. 
Results – Ireland
Prevalence
Sedatives or tranquillisers (Table 1)
One-in-ten respondents (11%) aged 15-64 reported that they 
had taken sedatives or tranquillisers at some stage in their lives, 
one-in-twenty (5%) had used them last year and 3% had used 
them last month.
Anti-depressants
Similarly, less than one-in-ten respondents (9%) aged 15-64 
reported that they had ever used anti-depressants, 4% had used 
them in the last year and 3% had used them in the last month.
Age (Table )
Sedatives or tranquillisers
The lifetime prevalence rate for older adults aged 35-64 (15%) 
was more than twice that for young adults aged 15-34 (6%). 
Older adults also had higher last year and last month prevalence 
rates (7% and 4% respectively) than young adults (3% and 1% 
respectively).
Anti-depressants
Similar results were found for anti-depressants, with older adults 
more likely than young adults to have used them at some stage 
in their lives, in the last year and in the last month. The lifetime 
prevalence rate for older adults aged 35-64 (11%) was higher 
than that for young adults (15-34) (7%). Older adults also had 
higher last year (5%) and last month (4%) prevalence rates 
compared to 3% and 2% respectively for young adults.
Gender (Table )
Female respondents reported higher prevalence rates than males 
across all time periods.
Sedatives or tranquillisers
Females reported higher prevalence rates for lifetime (13% 
compared to 8%), last year (6% compared to 4%) and last 
month use (4% compared to 2%).
Anti-depressants
The lifetime prevalence rate for females (13%) was twice that 
for males (6%). Similarly, the figures for last year use were 6% 
for females and 3% for males, whilst the last month prevalence 
rate for females was 4% and 2% for males.
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First use (Table 2)
Sedatives or tranquillisers
The average3 age respondents aged 15-64 reported that they 
had first used sedatives or tranquillisers was 30 years. The figure 
was 29 years for males and 31 years for females. The median 
age at which younger respondents (aged 15-34) reported first 
using sedatives or tranquillisers was at 22 years whereas the 
median age at which older respondents (aged 35-64) reported 
first use was 35 years.
Anti-depressants
The average (median) age that respondents aged 15-64 
reported that they had first used anti-depressants was 32 years. 
The figure was 34 for males and 30 for females. Younger 
respondents (aged 15-34) reported first using anti-depressants 
at 21 years. Older respondents (aged 35-64) reported an 
average age of first use of anti-depressants at 35 years.
Frequency of use (Table )
Sedatives or tranquillisers
More than half (57%) of the current users of sedatives or 
tranquillisers reported use on a daily or almost daily basis, 6% 
reported use several times a week, 17% used them at least 
once a week and 20% used them less than once a week. The 
frequency with which males and females used sedatives or 
tranquillisers did not differ greatly. Six-in-ten (60%) female and 
53% of male current sedative or tranquilliser users reported daily 
or almost daily use.
Anti-depressants
More than nine-in-ten (91%) current anti-depressants users 
reported daily or almost daily use, 5% used them several times 
a week, 2% used them at least once a week and 2% used them 
less than once a week. The frequency with which males and 
females used anti-depressants did not differ greatly. The vast 
majority of both female (95%) and male (86%) current anti-
depressant users reported daily or almost daily use.
Method of taking sedatives or tranquillisers, 
and anti-depressants (Table )
Sedatives or tranquillisers
Nearly all (99%) current users of sedatives or tranquillisers 
reported taking them orally (in the form of tablets or syrup); 0.5% 
of current users reported injecting sedatives or tranquillisers. No 
females (0.0%) reported injecting but 2% of males did.
3 The median was used to measure central tendency in the case of age  
of first use to avoid extreme values skewing the results. 
4 This was a multi-choice question and therefore percentages will not  
equal 100%.
Anti-depressants
Nearly all (99%) current users of anti-depressants reported 
taking them orally (in the form of tablets or syrup); 0.7% 
injected anti-depressants. No females (0.0%) reported injecting 
but 2% of males did.
How sedatives or tranquillisers, and anti-
depressants were obtained (Table )
All current users of sedatives or tranquillisers, and anti-
depressants were asked how they had obtained their drugs.
Sedatives or tranquillisers
The majority (89%) of current sedative or tranquilliser users got 
them on prescription; 7% said that they got them from someone 
else they knew and 2% had bought them without a prescription 
in a chemist. Older adults aged 35-64 (92%) were more likely 
then young adults aged 15-34 (77%) to report having got 
sedatives or tranquillisers on prescription. Twice as many young 
adults (13%) got them from someone they knew compared 
with older adults (6%). Over three times as many males (13%) 
than females (4%) got them from someone they knew.
Anti-depressants
The vast majority of anti-depressant users (99%) had got them 
on prescription; only 0.5% had bought them without a 
prescription in a chemist. No males reported buying them 
without a prescription whereas 1% of females did. All older 
adults (aged 35-64) reported buying them on prescription 
whereas 2% of young adults (aged 15-34) reported buying 
them without a prescription in a chemist.
User profile – sedatives or tranquillisers, and 
anti-depressants
For the purpose of the statistical tests detailed below a user was 
defined as someone who has ever used sedatives or tranquillisers, 
or anti-depressants. Tests were performed on the data for lifetime, 
last year and last month prevalence rates where appropriate.
Gender (Table 6)
Sedatives or tranquillisers
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
gender and use of sedatives or tranquillisers. Females are more 
likely than males to have ever used sedatives or tranquillisers 
(13% compared to 8%) to have used them in the last twelve 
months (6% compared to 4%) and to have used them in the 
last month (4% compared to 2%).
 National Advisory Committee on Drugs (NACD) & Public Health Information and Research Branch (PHIRB) March 2009
Drug Use in Ireland & Northern Ireland 2006/2007 Drug Prevalence Survey:  
Sedatives or Tranquillisers, and Anti-depressants Results Bulletin 6
9National Advisory Committee on Drugs (NACD) & Public Health Information and Research Branch (PHIRB) March 2009
Anti-depressants
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
gender and use of anti-depressants across all three time periods. 
Females are more likely than males to have ever used anti-
depressants (13% compared to 6%), to have used them in the 
last twelve months (6% compared to 3%) and to have used 
them in the last month (4% compared to 2%).
Age (Table 7)
Sedatives or tranquillisers
The results of all three chi-square testes were statistically 
significant. This indicates that there is an association between 
age and use of sedatives or tranquillisers. Older respondents 
aged 35-64 reported higher prevalence rates than young adults 
aged 15-34 across all three time periods: Lifetime (15% 
compared to 6%); last year (7% compared to 3%); and last 
month (4% compared to 1%).
Anti-depressants
The results of all three chi-square testes were statistically 
significant. This indicates that there is an association between age 
and use anti-depressants. Older respondents aged 35-64 
reported higher prevalence rates than young adults aged 15-34 
across all three time periods: Lifetime (11% compared to 7%); 
last year (5% compared to 3%); and last month (4% compared 
to 2%).
Socio-economic group (SEG) (Table )
Sedatives or tranquillisers
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
SEG and use of sedatives or tranquillisers on a lifetime, last  
year or last month basis. Respondents from SEG category E (all 
those dependent on the State long term) reported higher than 
expected prevalence rates across all three time periods. 
However, generally those in Category A also had a higher than 
expected prevalence rates across lifetime and last year periods.
Anti-depressants
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
SEG and use of anti-depressants on a lifetime, last year or last 
month basis. Respondents from SEG category E (all those 
dependent on the State long term) reported higher than 
expected prevalence rates across all three time periods. 
However, generally those in Category A also had a higher than 
expected prevalence rates across lifetime, last year and last 
month periods.
5 See classification of Socio-Economic Groups on page 5.
Work Status (Table 9)
Sedatives or tranquillisers
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association between 
work status and use of sedatives or tranquillisers. Respondents 
who reported they were not in paid work had higher than 
expected prevalence rates across all three time periods.
Anti-depressants
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association between 
work status and use of anti-depressants. Respondents who 
reported they were not in paid work had higher than expected 
prevalence rates across all three time periods.
Housing tenure (Table 0)
Sedatives or tranquillisers
The results of two of the three chi-square tests were statistically 
significant. This indicates that there is an association between 
housing tenure and lifetime and last year use of sedatives or 
tranquillisers. Respondents who rented their houses from a local 
authority or housing association reported higher levels of use on 
a lifetime and last year basis.
Anti-depressants
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association between 
housing tenure and use of anti-depressants. Respondents who 
rented their houses from a local authority or housing association 
reported higher levels of use on a lifetime, last year and last 
month basis.
Age education ceased (Table )
Sedatives or tranquillisers
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association between age 
education ceased and use of sedatives or tranquillisers. A 
general trend was observed where those respondents who had 
ceased education aged 15 years or under had higher than 
expected prevalence rates on a lifetime, last year and last month 
basis.
Anti-depressants
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association between 
age education ceased and use of anti-depressants. A general 
trend was observed where those respondents who had ceased 
education aged 15 years or under had higher than expected 
prevalence rates on a lifetime, last year and last month basis.
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Education level (Table 2)
Sedatives or tranquillisers
The results of all three chi-square tests were statistically significant. 
This indicates that there is an association between education level 
and use of sedatives or tranquillisers. Respondents who had 
obtained a primary school only level of education had higher  
than expected prevalence rates on a lifetime, last year and last 
month basis.
Anti-depressants
The results of all three chi-square tests were statistically significant. 
This indicates that there is an association between education level 
and use of anti-depressants. Respondents who had obtained a 
primary school only level of education had higher than expected 
prevalence rates on a lifetime, last year and last month basis.
Marital Status (Table )
Sedatives or tranquillisers
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
marital status and use of sedatives or tranquillisers. Respondents 
who were separated or divorced reported higher prevalence 
rates than expected over the three time periods.
Anti-depressants
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
marital status and use of anti-depressants. Respondents who 
were separated or divorced reported higher prevalence rates 
than expected over the three time periods.
Results – Northern Ireland
Prevalence (Table )
Sedatives or tranquillisers
One-in-five (20%) respondents aged 15-64 reported that they 
had used sedatives or tranquillisers at some stage in their lives 
while fewer than one-in-ten respondents have used them in the 
last year (9%) and in the last month (7%).
Anti-depressants
Similarly, just over one-in-five (21%) of all adults reported 
lifetime use of anti-depressants, 9% have used them in the  
last year and 8% have used them in the last month.
Age (Table )
Sedatives or tranquillisers
The lifetime prevalence rate for those aged 35-64 (26%) was 
twice than that of those aged 15-34 (12%). Older adults were 
also more than twice as likely as young adults to have used 
sedatives or tranquillisers in the last year (13% compared to 
5%) and more than five times as likely to have used them in  
the last month (11% compared to 2%).
Anti-depressants
Similar results were found for anti-depressants, with older adults 
more likely than young adults to have used them at some stage 
in their lives, in the last year and in the last month. The lifetime 
prevalence rate for those aged 35-64 (27%) was nearly twice 
that of those aged 15-34 (14%). Older adults also had higher 
last year and last month prevalence rates (12% and 10%, 
respectively) than young adults (6% and 4%, respectively). 
Gender (Table )
Sedatives or tranquillisers
Females reported higher prevalence rates than males for lifetime 
(22% compared to 18%) and last month (8% compared to 
6%) use of sedatives or tranquillisers. A similar proportion of 
females (10%) and males (8%) reported last year use of  
these drugs.
Anti-depressants
Prevalence rates for anti-depressants were higher among females 
than males across all time periods. The lifetime prevalence rate for 
females was 28% and 13% for males; the last year prevalence 
rate was 12% for females and 6% for males; and the last month 
prevalence rate was 11% for females and 4% for males.
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First use (Table )
Sedatives or tranquillisers
The average6 age that all adults reported they had first used 
sedatives or tranquillisers was 30 years; this was true for both 
males and females. Young adults aged 15-34 reported first using 
sedatives or tranquillisers at 18 years while older adults aged 35-
64 reported an average age of first use of 35 years.
Anti-depressants
The average6 age that respondents aged 15-64 reported they 
had first used anti-depressants was 32 years; the corresponding 
age for males was 34 years and 31 years for females. Young 
adults aged 15-34 reported first using anti-depressants at 21 
years with older adults aged 35-64 first using them at 37 years.
Frequency of use (Table 6)
Sedatives or tranquillisers
Nearly two-in-three (66%) current users of sedatives or 
tranquillisers take them on a daily or almost daily basis, 7% use 
them several times a week, 13% use them at least once a week 
and 15% use them less than once a week.
Anti-depressants
Nearly nine-in-ten (87%) current users of anti-depressants use 
them daily or almost daily, 3% use them several times a week, 
5% use them at least once a week and 5% use them less than 
once a week.
Method of taking sedatives or tranquillisers, 
and anti-depressants (Table 7)
Sedatives or tranquillisers
Nearly all (99%) current users of sedatives or tranquillisers 
reported taking them orally (in the form of tablets or syrup). No 
current users of sedatives or tranquillisers reported injecting them 
with a needle, although 1% took them by some other method.
Anti-depressants
All (100%) current users of anti-depressants reported taking 
them orally.
How sedatives or tranquillisers, and anti-
depressants were obtained (Table )
All current users of sedatives or tranquillisers, and anti-
depressants were asked how they had obtained their drugs.
6 The median was used to measure central tendency in the case of age of 
first use to avoid extreme values skewing the results. 
Sedatives or tranquillisers
The vast majority (95%) of current users of sedatives or 
tranquillisers got them on prescription. A further 2% got them 
from someone they know, 2% bought them without a 
prescription in a chemist, and 1% bought them over the Internet. 
Among current users, at least nine-in-ten females (98%) and 
males (90%) reported getting their sedatives or tranquillisers on 
prescription. All (100%) young adults aged 15-34 and 94% of 
older adults aged 35-64 who are current users of sedatives or 
tranquillisers got them on prescription.
Anti-depressants
Similarly, more than nine-in-ten (96%) current users of anti-
depressants got them on prescription, 2% got them from 
someone they know, and 2% bought them without a 
prescription in a chemist. The vast majority of female (98%) and 
male (90%) current users of anti-depressants got them on 
prescription. Just over nine-in-ten (91%) young adults got their 
anti-depressants on prescription, 5% got them from someone 
they knew and 4% got them from the chemist without a 
prescription, whereas 97% of older adults who are current users 
got their anti-depressants on prescription, 1% got them from 
someone they knew and 2% got them from the chemist without 
a prescription.
User profile – sedatives or tranquillisers, and 
anti-depressants
For the purpose of the statistical tests detailed below a user was 
defined as someone who has ever used sedatives or 
tranquillisers, or anti-depressants.
Tests were performed on the data for lifetime, last year and last 
month prevalence rates where appropriate.
Gender (Table 9)
Sedatives or tranquillisers
The results of two of the three chi-square tests were statistically 
significant. This indicates that there is an association between 
gender and lifetime and last month use of sedatives or 
tranquillisers. Females are more likely than males to have ever 
used sedatives or tranquillisers (22% compared to 18%) or to 
have used them in the last month (8% compared to 6%).
Anti-depressants
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
gender and use of anti-depressants across all three time periods. 
Females are more likely than males to have ever used anti-
depressants (28% compared to 13%), to have used them in the 
last year (12% compared to 6%) and to have used them in the 
last month (11% compared to 4%).
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Age (Table 20)
Sedatives or tranquillisers
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
age and use of sedatives or tranquillisers. Older adults aged  
35-64 reported higher prevalence rates than young adults aged 
15-34 across all three time periods: lifetime (26% compared  
to 12%); last year (13% compared to 5%); and last month 
(11% compared to 2%).
Anti-depressants
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
age and use of anti-depressants. Older adults aged 35-64 
reported higher prevalence rates than young adults aged 15-34 
across all three time periods: lifetime (27% compared to 14%); 
last year (12% compared to 6%); and last month (10% 
compared to 4%).
National Statistics Socio-Economic 
Classifications (NSSEC)7 (Table 2)
Sedatives or tranquillisers
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
NSSEC and use of sedatives or tranquillisers on a lifetime,  
last year and last month basis. Respondents from the NSSEC 
categories ‘Semi-routine and routine occupations’ and ‘Never 
worked and long term unemployed’ reported higher than 
expected prevalence rates across all three time periods.
Anti-depressants
The results of all three chi-square tests were statistically significant. 
This indicates that there is an association on a lifetime, last year 
and last month basis between NSSEC and use of anti-depressants. 
Respondents from the NSSEC categories ‘Semi-routine and routine 
occupations’ and ‘Never worked and long term unemployed’ 
reported higher than expected prevalence rates across all three 
time periods.
Work status (Table 22)
Sedatives or tranquillisers
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association between 
work status and use of sedatives or tranquillisers. Respondents 
who reported they were not in paid work had higher than 
expected prevalence rates across all three time periods.
7 See categories of National Statistics Socio-Economic Classifications on 
page 5.
Anti-depressants
The results of the three chi-square tests were statistically 
significant. This indicates that there is an association between 
work status and use of anti-depressants. Respondents who 
reported they were not in paid work had higher than expected 
prevalence rates across all three time periods.
Housing tenure (Table 2)
Sedatives or tranquillisers
Due to small cell counts the chi-square test was not appropriate 
to determine any association between housing tenure and the 
use of sedatives or tranquillisers across all three time periods.
Anti-depressants
Due to small cell counts the chi-square test was not appropriate 
to determine any association between housing tenure and the 
use of anti-depressants across all three time periods.
Education level (Table 2)
Sedatives or tranquillisers
The results of all three chi-square tests were statistically significant. 
This indicates that there is an association between education level 
and use of sedatives or tranquillisers. Respondents who had 
either no qualifications or who had attained GCSE D-G grades as 
their highest qualification level reported higher prevalence rates 
than expected on a lifetime, last year and last month basis.
Anti-depressants
The results of all three chi-square tests were statistically 
significant. This indicates that there is an association between 
education level and use of anti-depressants. Respondents who 
had either no qualifications or who had attained GCSE D-G 
grades as their highest qualification level reported higher 
prevalence rates than expected across all three time periods.
Marital Status (Table 2)
Sedatives or tranquillisers
Due to small cell counts, the chi-square test was only appropriate 
for lifetime prevalence data and returned a significant result. This 
indicates an association between marital status and lifetime use 
of sedatives or tranquillisers. Respondents who were co-habiting, 
separated, divorced or widowed reported higher prevalence rates 
than expected.
Anti-depressants
Due to small cell counts, the chi-square test was only appropriate 
for lifetime prevalence data and returned a significant result. This 
indicates an association between marital status and lifetime use 
of anti-depressants. Respondents who were separated, divorced 
or widowed reported higher prevalence rates than expected.
2 National Advisory Committee on Drugs (NACD) & Public Health Information and Research Branch (PHIRB) March 2009
Drug Use in Ireland & Northern Ireland 2006/2007 Drug Prevalence Survey:  
Sedatives or Tranquillisers, and Anti-depressants Results Bulletin 6
Comparison – Ireland and 
Northern Ireland
Prevalence
In all instances the use of sedatives or tranquillisers, and anti-
depressants was higher in Northern Ireland than in Ireland.
Sedatives or tranquillisers
The figure for lifetime use in Northern Ireland (20%) was nearly 
double that reported for Ireland (11%). The figures for recent 
use were similarly proportioned. The last year prevalence rate 
was 9% in Northern Ireland and 5% in Ireland. Likewise, the 
figure for current use was higher in Northern Ireland (7%) than  
it was in Ireland (3%).
Anti-depressants
Similarly, the figure for lifetime use in Northern Ireland (21%) 
was over double that reported for Ireland (9%). The figures for 
recent use were similarly proportioned. The last year prevalence 
rate was 9% in Northern Ireland and 4% in Ireland. Likewise, the 
figure for current use was higher in Northern Ireland (8%) than it 
was in Ireland (3%).
Obtaining sedatives or tranquillisers, and anti-
depressants
Throughout Ireland and Northern Ireland the pattern was the 
same – nearly all users of sedatives or tranquillisers, and anti-
depressants took tablets or syrup that they had obtained on 
prescription.
Profile of users
The profile of those who used sedatives or tranquillisers, and 
anti-depressants was similar in both jurisdictions.
In general, females and older respondents reported higher 
prevalence rates. These associations were found to be statistically 
significant among females for all usage of sedatives or 
tranquillisers in Ireland and for lifetime and last month use in 
Northern Ireland, and among older adults across the three time 
periods for both jurisdictions. Use of anti-depressants was higher 
among females and older adults aged 35-64 across all time 
periods in Ireland and Northern Ireland.
In Ireland, there were statistically significant associations between 
marital status and use of sedatives or tranquillisers, and anti-
depressants on a lifetime, last year and last month basis. 
However, in Northern Ireland there was only an association 
between marital status and lifetime use. Nonetheless, 
respondents who were separated, divorced or widowed in both 
jurisdictions were more likely to use sedatives or tranquillisers, 
and anti-depressants.
Significant associations were also found between social class and 
the use of sedatives or tranquillisers, and anti-depressants. Those 
respondents who were dependent upon the State long term in 
Ireland, and those who had never worked or were long-term 
unemployed in Northern Ireland, reported higher prevalence 
rates. Similarly, associations between working status and use of 
these drugs were also noted. Those who were not in paid work 
in both Ireland and Northern Ireland reported higher prevalence 
rates across all three time periods.
Further associations were found between educational level 
attained in Ireland (lower levels of attainment such as ‘primary 
school’ only were associated with higher levels of use) and 
qualification level attained in Northern Ireland (those with no 
qualifications or who had attained GCSE D-G grades as their 
highest qualification reported higher prevalence rates). Significant 
associations were also found between age education ceased and 
use of sedatives or tranquillisers, and anti-depressants in Ireland 
on a lifetime, last year and last month basis. A higher proportion 
of respondents who left school before 15 years-of-age reported 
using sedatives or tranquillisers, and anti-depressants.
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Table 1: Ireland



















Total Weighted N (valid responses) (4967) (2513) (2454) (2315) (2652) (4967) (2513) (2454) (2315) (2652)
Lifetime Prevalence 10.5 8.0 13.2 5.9 14.6 9.2 5.9 12.5 7.1 10.9
Last Year Prevalence (Recent use) 4.7 3.7 5.7 2.5 6.5 4.3 3.0 5.6 3.2 5.2
Last Month Prevalence (Current use) 3.0 2.4 3.5 1.3 4.4 3.1 2.3 3.9 2.2 3.9
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 2: Ireland



















Total Weighted N (valid responses) (524) (201) (323) (136) (388) (455)◆ (149) (306) (164) (290) 
Mean age of first use 32 31 33 23 36 32 34 30 22 37
Median age of first use1 30 29 31 22 35 32 34 30 21 35
1 Median is used as a measure of central tendency to avoid extreme values skewing results.
◆ Due to weighting, age categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are based on valid responses.
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Table 3: Ireland




















Total Weighted N (valid responses) (147) (60) (87) (29) (118) (152)◆ (56) (94) (51) (101) 
20 days or more 57.1 53.3 59.8 41.4 61.0 91.1 87.5 94.7 92.2 90.1
10-19 days 6.2 5.0 6.9 3.4 6.8 4.9 7.1 3.2 5.9 5.0
4-9 days 17.0 16.7 17.2 17.2 16.9 1.8 1.8 1.1 2.0 2.0
1-3 days 19.7 25.0 16.1 37.9 15.3 2.2 3.6 1.1 0.0 3.0
2 EMCDDA ‘Handbook for surveys on Drug Use Among the General Population’ (Aug 2002) defines frequency of drug use as:
20 days or more = daily or almost daily.
10-19 days = several times a week.
4-9 days = at least once a week.
1-3 days = less than once a week.
◆ Due to weighting, gender categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 4: Ireland




















Total Weighted N (valid responses) (147)◆  (60)  (87)  (30)  (118) (153)◆ (58) (96) (50) (103) 
Oral (Tablets or Syrup) 99.5 98.4 100 100 99.2 99.3 98.3 100 100 99
Injection with a Needle 0.5 1.6 0.0 0.0 0.8 0.7 1.7 0.0 0.0 1.0
Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
◆ Due to weighting, gender and/or age categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 5: Ireland




















Total Weighted N (valid responses) (147)◆ (61) (86) (31) (117) (154) (58) (96) (51) (103) 
I got them on prescription 89.4 83.6 93.0 77.4 92.3 99.5 100 99.0 98.0 100
I got them from someone I know 7.4 13.1 3.5 12.9 6.0 0.0 0.0 0.0 0.0 0.0
I bought them without a prescription in a chemist 2.2 0.0 3.5 3.2 1.7 0.5 0.0 1.0 2.0 0.0
I bought them over the Internet 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Other 1.1 3.3 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0
◆ Due to weighting, age categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
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Table 7: Ireland
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Table 8: Ireland
Sedatives or Tranquillisers Prevalence by Socio-Economic Group (%)
A B C C2 D E Total
Lifetime*
Total Weighted N (valid responses) (232) (868) (1423) (1111) (799) (485) (4918) 
No 86.6 89.8 89.5 91.8 91.5 81.2 89.5
Yes 13.4 10.1 10.5 8.2 8.5 18.8 10.5
Last Year*
Total Weighted N (valid responses) (232) (868) (1424) (1111) (800) (486) (4921)
No 93.5 96.0 95.8 96.8 95.9 89.3 95.3
Yes 6.5 4.0 4.2 3.2 4.1 10.7 4.7
Last Month*
Total Weighted N (valid responses) (232) (868) (1424) (1111) (800) (486) (4923)◆
No 97.0 97.7 97.4 98.6 97.1 91.2 97.0
Yes 3.0 2.3 2.6 1.4 2.9 8.8 3.0
* p <0.05 (Sedatives or tranquillisers)
◆ Due to weighting, SEG categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 8: Ireland (continued)
Anti-depressants Prevalence by Socio-Economic Group (%)
A B C1 C2 D E Total
Lifetime**
Total Weighted N (valid responses) (232) (869) (1424) (1111) (799) (485) (4922)◆
No 89.2 94.0 91.6 92.2 91.4 79.4 90.8
Yes 10.8 6.0 8.4 7.8 8.6 20.6 9.2
Last Year**
Total Weighted N (valid responses) (232) (868) (1424) (1111) (799) (485) (4920)◆
No 94.8 97.2 96.7 97.0 96.0 86.8 95.7
Yes 5.2 2.8 3.3 3.0 4.0 13.2 4.3
Last Month**
Total Weighted N (valid responses) (232) (869) (1423) (1111) (799) (485) (4920)◆
No 96.6 97.8 97.7 97.8 97.6 89.9 96.9
Yes 3.4 2.2 2.3 2.2 2.4 10.1 3.1
** p <0.05 (Anti-depressants)
◆ Due to weighting, SEG categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 9: Ireland










work Student Other Total
Lifetime*,**
Total Weighted N (valid responses) (3202) (1228) (525) (11) (4966) (3202) (1228) (525) (11) (4966)
No 90.8 82.8 96.8 100.0 89.5 92.8 83.1 96.8 100.0 90.9
Yes 9.2 17.2 3.2 0.0 10.5 7.2 16.9 3.2 0.0 9.1
Last Year*,**
Total Weighted N (valid responses) (3202) (1228) (525) (11) (4966) (3203) (1229) (525) (11) (4967)
No 96.7 90.6 98.5 100.0 95.3 97.3 90.5 98.5 100.0 95.7
Yes 3.3 9.4 1.5 0.0 4.7 2.7 9.5 1.5 0.0 4.3
Last Month*,**
Total Weighted N (valid responses) (3202) (1228) (526) (11) (4967) (3203) (1228) (525) (11) (4967)
No 98.2 92.8 99.8 100.0 97.0 98.2 92.8 98.9 100.0 96.9
Yes 1.8 7.2 0.2 0.0 3.0 1.8 7.2 1.1 0.0 3.1
* p <0.05 (Sedatives or tranquillisers)
** p <0.05 (Anti-depressants)
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 10: Ireland






















Total Weighted N (valid responses) (3521) (932) (466) (47) (4968)◆ (3522) (932) (467) (48) (4969)
No 89.3 90.5 87.3 100.0 89.5 91.9 89.5 84.6 95.8 90.8
Yes 10.7 9.5 12.7 0.0 10.5 8.1 10.5 15.4 4.2 9.2
Last Year*,**
Total Weighted N (valid responses) (3521) (932) (466) (47) (4966) (3522) (932) (466) (48) (4968)
No 95.5 95.9 92.7 100.0 95.3 96.3 94.8 92.3 100.0 95.7
Yes  4.5 4.1 7.3 0.0 4.7 3.7 5.2 7.7 0.0 4.3
Last Month**
Total Weighted N (valid responses) (3521) (931) (466) (47) (4965) (3522) (932) (466) (48) (4968)
No 97.2 97.3 95.3 100.0 97.1 97.3 97.0 93.6 100.0 96.9
Yes 2.8 2.7 4.7 0.0 2.9 2.7 3.0 6.4 0.0 3.1
* p <0.05 (Sedatives or tranquillisers)
** p <0.05 (Anti-depressants)
◆ Due to weighting, housing tenure categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
LA/HA = Local Authority or Housing Association
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Table 11: Ireland



















Total Weighted N (valid responses) (516) (1925) (1416) (3857) (516) (1925) (1416) (3857)
No 83.1 89.7 88.8 88.5 85.1 89.7 92.5 90.1
Yes 16.9 10.3 11.2 11.5 14.9 10.3 7.5 9.9
Last Year*,**
Total Weighted N (valid responses) (516) (1925) (1416) (3857) (516) (1924) (1415) (3855)
No 91.5 95.1 95.5 94.8 91.7 95.7 96.4 95.4
Yes 8.5 4.9 4.5 5.2 8.3 4.3 3.6 4.6
Last Month*,**
Total Weighted N (valid responses) (516) (1925) (1416) (3857) (516) (1925) (1416) (3857)
No 93.0 96.7 97.7 96.6 93.2 96.8 97.7 96.7
Yes 7.0 3.3 2.3 3.4 6.8 3.2 2.3 3.3
* p <0.05 (Sedatives or tranquillisers)
** p <0.05 (Anti-depressants)
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 12: Ireland




















Total Weighted N (valid responses) (324) (1472) (1196) (1967) (4959) (324) (1472) (1195) (1967) (4958)
No 83.3 90.1 91.5 88.7 89.5 86.1 89.9 91.0 92.2 90.8
Yes 16.7 9.9 8.5 11.3 10.5 13.9 10.1 9.0 7.8 9.2
Last Year*,**
Total Weighted N (valid responses) (324) (1473) (1195) (1966) (4958) (324) (1472) (1195) (1966) (4957) 
No 92.0 95.4 96.0 95.5 95.4 91.7 95.2 95.9 96.6 95.7
Yes 8.0 4.6 4.0 4.5 4.6 8.3 4.8 4.1 3.4 4.3
Last Month*,**
Total Weighted N (valid responses) (324) (1472) (1195) (1967) (4958) (324) (1472) (1196) (1967) (4959) 
No 93.8 96.6 97.7 97.5 97.0 93.5 96.4 97.2 97.7 96.9
Yes 6.2 3.4 2.3 2.5 3.0 6.5 3.6 2.8 2.3 3.1
* p <0.05 (Sedatives or tranquillisers)
** p <0.05 (Anti-depressants)
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 13: Ireland
Sedatives or Tranquillisers Prevalence by Marital Status (%)
Single Married Co-habiting Separated Divorced Widowed Total
Lifetime*
Total Weighted N (valid responses) (1965) (2310) (346) (167) (80) (96) (4965)◆
No 92.5 88.7 90.5 77.8 73.8 74.0 89.5
Yes 7.5 11.3 9.5 22.2 26.3 26.0 10.5
Last Year*
Total Weighted N (valid responses) (1965) (2310) (346) (166) (80) (96) (4963) 
No 96.1 95.5 96.8 89.2 85.0 90.6 95.3
Yes 3.9 4.5 3.2 10.8 15.0 9.4 4.7
Last Month*
Total Weighted N (valid responses) (1965) (2310) (346) (166) (80) (96) (4963) 
No 97.4 97.0 99.1 95.2 91.3 92.7 97.0
Yes 2.6 3.0 0.9 4.8 8.7 7.3 3.0
* p <0.05 (Sedatives or tranquillisers)
◆ Due to weighting, marital status categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 13: Ireland (continued)
Anti-depressants Prevalence by Marital Status (%)
Single Married Co-habiting Separated Divorced Widowed Total
Lifetime**
Total Weighted N (valid responses) (1965) (2309) (345) (167) (80) (96) (4962) 
No 92.6 90.8 91.0 80.2 82.5 82.3 90.9
Yes  7.4  9.2 9.0 19.8 17.5 17.7 9.1
Last Year**
Total Weighted N (valid responses) (1965) (2309) (345) (167) (80) (96) (4962) 
No 95.7 96.2 96.8 89.8 88.8 95.8 95.7
Yes 4.3 3.8 3.2 10.2 11.3 4.2 4.3
Last Month**
Total Weighted N (valid responses) (1965) (2309) (346) (167) (80) (96) (4963) 
No 96.6 97.2 98.8 94.0 93.8 95.8 96.9
Yes 3.4 2.8 1.2 6.0 6.3 4.2 3.1
** p <0.05 (Anti-depressants)
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 14: Northern Ireland



















Total Weighted N (valid responses) (2002) (993) (1009) (844)Ü (1150)Ü (2000)◆ (992) (1009) (843)Ü (1150)Ü
Lifetime Prevalence 20.2 18.1 22.3 11.7 26.5 21.0 13.4 28.4 13.6 26.6
Last Year Prevalence (Recent use) 9.2 8.2 10.2 4.6 12.6 9.1 5.8 12.4 5.8 11.7
Last Month Prevalence (Current use) 7.1 5.7 8.4 2.3 10.7 7.5 4.2 10.7 4.2 10.0
◆ Due to weighting, gender and/or age categories do not always sum to total weighted N.
Ü Eight respondents confirmed they were eligible to take part in the survey but did not state their exact age.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 15: Northern Ireland



















Total Weighted N (valid responses) (404) (179) (225) (99) (304) (419) (132) (287) (114) (305)
Mean age of first use 31 31 32 20 35 33 35 33 22 38
Median age of first use 1 30 30 30 18 35 32 34 31 21 37
1 Median is used as a measure of central tendency to avoid extreme values skewing results.
All figures are based on weighted data.
All figures are based on valid responses.
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Table 16: Northern Ireland




















Total Weighted N (valid responses) (142) (57) (85) (19) (123) (150) (42) (108) (35) (115)
20 days or more 65.6 50.2 75.8 51.1 67.8 86.8 70.9 93.0 74.4 90.6
10-19 days 7.2 11.7 4.2 0.0 8.3 3.4 6.4 2.3 8.0 2.0
4-9 days 12.6 20.4 7.4 34.6 9.2 4.6 9.6 2.7 12.9 2.1
1-3 days 14.7 17.7 12.7 14.3 14.7 5.1 13.1 2.0 4.7 5.2
2 EMCDDA ‘Handbook for surveys on Drug Use Among the General Population’ (Aug 2002) defines frequency of drug use as:
20 days or more = daily or almost daily.
10-19 days = several times a week.
4-9 days = at least once a week.
1-3 days = less than once a week.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
Table 17: Northern Ireland




















Total Weighted N (valid responses) (142) (57) (85) (19) (123) (150) (42) (108) (35) (115)
Oral (Tablets or Syrup) 98.6 100.0 97.6 100.0 98.4 100.0 100.0 100.0 100.0 100.0
Injection with a Needle 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Other 1.4 0.0 2.4 0.0 1.6 0.0 0.0 0.0 0.0 0.0
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 18: Northern Ireland




















Total Weighted N (valid responses) (142) (57) (85) (19) (123) (150) (42) (108) (35) (115)
I got them on prescription 94.8 89.6 98.2 100.0 94.0 95.8 90.3 97.9 91.3 97.1
I got them from someone I know 2.2 5.5 0.0 0.0 2.5 2.1 7.4 0.0 4.7 1.3
I bought them without a prescription in a chemist 1.6 1.3 1.8 0.0 1.9 2.2 2.3 2.1 4.0 1.6
I bought them over the Internet 1.2 2.9 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0
Other 0.3 0.7 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 19: Northern Ireland
Sedatives or Tranquillisers Prevalence by Gender (%) Anti-depressants Prevalence 
by Gender (%)
 Male Female Total Male Female Total
Lifetime*,**
Total Weighted N (valid responses) (993) (1009) (2002) (992) (1009) (2000)◆
No 81.9 77.7 79.8 86.6 71.6 79.0
Yes 18.1 22.3 20.2 13.4 28.4 21.0
Last Year**
Total Weighted N (valid responses) (993) (1009) (2002) (992) (1009) (2000)◆
No 91.8 89.8 90.8 94.2 87.6 90.9
Yes 8.2 10.2 9.2 5.8 12.4 9.1
Last Month*,**
Total Weighted N (valid responses) (993) (1009) (2002) (992) (1009) (2000)◆
No 94.3 91.6 92.9 95.8 89.3 92.5
Yes 5.7 8.4 7.1 4.2 10.7 7.5
* p <0.05 (Sedatives or tranquillisers)
** p <0.05 (Anti-depressants)
◆ Due to weighting, gender categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 20: Northern Ireland
Sedatives or Tranquillisers Prevalence by Age Group (%) Anti-depressants Prevalence 














Total Weighted N (valid responses) (844) (1150) (1994) (843) (1150) (1992)◆
No 88.3 73.5 79.8 86.4 73.4 79.0
Yes 11.7 26.5 20.2 13.6 26.6 21.0
Last Year*,**
Total Weighted N (valid responses) (844) (1150) (1994) (843) (1150) (1992)◆
No 95.4 87.4 90.8 94.2 88.3 90.9
Yes 4.6 12.6 9.2 5.8 11.7 9.1
Last Month*,**
Total Weighted N (valid responses) (844) (1150) (1994) (843) (1150) (1992)◆
No 97.7 89.3 92.9 95.8 90.0 92.5
Yes 2.3 10.7 7.1 4.2 10.0 7.5
* p <0.05 (Sedatives or tranquillisers)
** p <0.05 (Anti-depressants)
◆ Due to weighting, age categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 21: Northern Ireland

































































































































Total Weighted N (valid responses) (534) (211) (202) (130) (637) (107) (172) (1994)◆
No 79.8 80.7 79.5 83.9 76.3 69.5 94.8 79.8
Yes 20.2 19.3 20.5 16.1 23.7 30.5 5.2 20.2
Last Year*
Total Weighted N (valid responses) (534) (211) (202) (130) (637) (107) (172) (1994)◆
No 93.2 91.1 93.4 94.4 86.6 82.4 97.6 90.8
Yes 6.8 8.9 6.6 5.6 13.4 17.6 2.4 9.2
Last Month*
Total Weighted N (valid responses) (534) (211) (202) (130) (637) (107) (172) (1994)◆
No 95.9 92.6 95.1 94.4 89.1 86.3 98.4 92.9
Yes 4.1 7.4 4.9 5.6 10.9 13.7 1.6 7.1
* p <0.05 (Sedatives or tranquillisers)
◆ Due to weighting, NSSEC categories do not sum to the total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 21: Northern Ireland (continued)

































































































































Total Weighted N (valid responses) (534) (211) (202) (130) (637) (106) (172) (1992)
No 82.6 78.7 83.4 84.1 71.2 68.7 93.6 79.0
Yes 17.4 21.3 16.6 15.9 28.8 31.3 6.4 21.0
Last Year**
Total Weighted N (valid responses) (534) (211) (202) (130) (637) (106) (172) (1992)
No 94.7 89.7 96.8 88.9 85.9 81.6 98.5 90.9
Yes 5.3 10.3 3.2 11.1 14.1 18.4 1.5 9.1
Last Month**
Total Weighted N (valid responses) (534) (211) (202) (130) (637) (106) (172) (1992)
No 95.5 93.0 98.2 89.5 88.1 84.4 98.9 92.5
Yes 4.5 7.0 1.8 10.5 11.9 15.6 1.1 7.5
** p <0.05 (Anti-depressants)
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 22: Northern Ireland













Total Weighted N (valid responses) (1243) (609) (150) (2002) (1243) (607) (150) (2000)
No 83.9 67.8 95.0 79.8 84.4 64.2 94.0 79.0
Yes 16.1 32.2 5.0 20.2 15.6 35.8 6.0 21.0
Last Year*,**
Total Weighted N (valid responses) (1243) (609) (150) (2002) (1243) (607) (150) (2000)
No 95.3 79.7 98.2 90.8 95.0 80.6 98.6 90.9
Yes 4.7 20.3 1.8 9.2 5.0 19.4 1.4 9.1
Last Month*,**
Total Weighted N (valid responses) (1243) (609) (150) (2002) (1243) (607) (150) (2000)
No 97.1 83.1 98.2 92.9 96.4 82.8 99.1 92.5
Yes 2.9 16.9 1.8 7.1 3.6 17.2 0.9 7.5
* p <0.05 (Sedatives or tranquillisers)
** p <0.05 (Anti-depressants)
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 23: Northern Ireland

















































































































Total Weighted N (valid responses) (527) (908) (5) (244) (38) (258) (16) (1998)◆
No 80.9 83.0 50.1 69.9 56.6 79.2 91.5 79.8
Yes 19.1 17.0 49.9 30.1 43.4 20.8 8.5 20.2
Last Year
Total Weighted N (valid responses) (527) (908) (5) (244) (38) (258) (16) (1998)◆
No 91.3 94.3 86.8 82.3 73.3 88.3 91.5 90.8
Yes 8.7 5.7 13.2 17.7 26.7 11.7 8.5 9.2
Last Month
Total Weighted N (valid responses) (527) (908) (5) (244) (38) (258) (16) (1998)◆
No 93.4 95.5 86.8 85.0 75.1 92.6 100.0 92.9
Yes 6.6 4.5 13.2 15.0 24.9 7.4 0.0 7.1
◆ Due to weighting, housing tenure categories do not sum to the total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 23: Northern Ireland (continued)

















































































































Total Weighted N (valid responses) (527) (908) (5) (244) (38) (256) (16) (1996)◆
No 82.6 82.6 46.9 64.8 49.0 76.6 91.6 79.0
Yes 17.4 17.4 53.1 35.2 51.0 23.4 8.4 21.0
Last Year
Total Weighted N (valid responses) (527) (908) (5) (244) (38) (256) (16) (1996)◆
No 92.6 93.8 86.8 81.4 78.1 87.3 95.6 90.9
Yes 7.4 6.2 13.2 18.6 21.9 12.7 4.4 9.1
Last Month
Total Weighted N (valid responses) (527) (908) (5) (244) (38) (256) (16) (1996)◆
No 93.5 95.1 86.8 84.4 80.1 90.4 95.6 92.5
Yes 6.5 4.9 13.2 15.6 19.9 9.6 4.4 7.5
◆ Due to weighting, housing tenure categories do not sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 24: Northern Ireland


































































































































Total Weighted N (valid responses) (310) (237) (355) (434) (159) (506) (2001) (310) (237) (355) (434) (159) (504) (2000)◆
No 84.5 78.7 83.3 83.1 70.6 75.2 79.8 86.1 80.8 84.1 77.5 70.9 74.0 79.0
Yes 15.5 21.3 16.7 16.9 29.4 24.8 20.2 13.9 19.2 15.9 22.5 29.1 26.0 21.0
Last Year*,**
Total Weighted N (valid responses) (310) (237) (355) (434) (159) (506) (2001) (310) (237) (355) (434) (159) (504) (2000)◆
No 95.6 91.0 94.5 91.4 86.8 85.9 90.8 96.0 92.1 94.3 91.2 86.4 85.8 90.9
Yes 4.4 9.0 5.5 8.6 13.2 14.1 9.2 4.0 7.9 5.7 8.8 13.6 14.2 9.1
Last Month*,**
Total Weighted N (valid responses) (310) (237) (355) (434) (159) (506) (2001) (310) (237) (355) (434) (159) (504) (2000)◆
No 98.0 93.7 95.7 94.2 88.5 87.7 92.9 97.1 93.8 95.1 93.4 88.1 87.8 92.5
Yes 2.0 6.3 4.3 5.8 11.5 12.3 7.1 2.9 6.2 4.9 6.6 11.9 12.2 7.5
* p <0.05 (Sedatives or tranquillisers)
** p <0.05 (Anti-depressants)
◆ Due to weighting, qualification categories do not always sum to total weighted N.
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 25: Northern Ireland





























































Total Weighted N (valid responses) (731) (900) (141) (83) (101) (40) (5) (2001)
No 84.1 81.9 75.5 52.1 63.9 67.8 79.5 79.8
Yes 15.9 18.1 24.5 47.9 36.1 32.2 20.5 20.2
Last Year
Total Weighted N (valid responses) (731) (900) (141) (83) (101) (40) (5) (2001)
No 91.3 93.2 93.7 75.2 78.3 83.1 79.5 90.8
Yes 8.7 6.8 6.3 24.8 21.7 16.9 20.5 9.2
Last Month
Total Weighted N (valid responses) (731) (900) (141) (83) (101) (40) (5) (2001)
No 94.7 94.3 94.7 81.1 78.8 85.3 79.5 92.9
Yes 5.3 5.7 5.3 18.9 21.2 14.7 20.5 7.1
* p <0.05 (Sedatives or tranquillisers)
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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Table 25: Northern Ireland (continued)





























































Total Weighted N (valid responses) (729) (900) (141) (83) (101) (40) (5) (1999)
No 82.6 80.4 79.3 52.3 61.9 77.9 84.8 79.0
Yes 17.4 19.6 20.7 47.7 38.1 22.1 15.2 21.0
Last Year
Total Weighted N (valid responses) (729) (900) (141) (83) (101) (40) (5) (1999)
No 91.7 92.3 94.0 74.8 81.5 89.5 84.8 90.9
Yes 8.3 7.7 6.0 25.2 18.5 10.5 15.2 9.1
Last Month
Total Weighted N (valid responses) (729) (900) (141) (83) (101) (40) (5) (1999)
No 93.2 93.7 95.3 79.8 84.0 89.5 100.0 92.5
Yes 6.8 6.3 4.7 20.2 16.0 10.5 0.0 7.5
** p <0.05 (Anti-depressants)
All figures are based on weighted data.
All figures are rounded to the nearest decimal place.
All figures are based on valid responses.
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LY = Last Year





























Purple boundary and shading highlights the RDTF areas.
HSSB areas are highlighted in pink shading.
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Purple boundary and shading highlights the RDTF areas.
HSSB areas are highlighted in pink shading.
Map 2
Use of Anti-depressants: Prevalence rates for all adults aged 15-64 in RDTF and HSSB areas 2006/2007
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